Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Total Debt (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Total Debt for 4 consecutive years, with $41313.0 as the latest value for Q4 2025.

  • Quarterly Total Debt rose 104.72% to $41313.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $41313.0 through Dec 2025, up 104.72% year-over-year, with the annual reading at $41313.0 for FY2025, 104.72% up from the prior year.
  • Total Debt for Q4 2025 was $41313.0 at bioAffinity Technologies, down from $43658.0 in the prior quarter.
  • The five-year high for Total Debt was $500000.0 in Q3 2022, with the low at $20180.0 in Q4 2024.
  • Average Total Debt over 4 years is $102437.6, with a median of $42996.0 recorded in 2023.
  • The sharpest move saw Total Debt tumbled 86.32% in 2024, then surged 109.04% in 2025.
  • Over 4 years, Total Debt stood at $251746.0 in 2022, then crashed by 83.18% to $42334.0 in 2023, then plummeted by 52.33% to $20180.0 in 2024, then soared by 104.72% to $41313.0 in 2025.
  • According to Business Quant data, Total Debt over the past three periods came in at $41313.0, $43658.0, and $45952.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.